Travere Therapeutics (TVTX) has just reshaped its balance sheet with a US$525 million public offering of 0.50% convertible senior notes due 2032, using a large portion to retire its existing 2029 convertible notes.

Travere’s recent refinancing comes after a powerful run in the stock, with a 90 day share price return of 53.09% and a 1 year total shareholder return of 153.51%. This suggests momentum has been strong even though the 1 day move was weaker around the latest capital raise and recent earnings update.

If this kind of financing activity has you thinking about where else capital may flow in healthcare, it could be a good moment to scan 32 healthcare AI stocks

With the stock up sharply over the past year and trading below some analysts’ price targets, the key question now is simple: Is Travere still undervalued after this refinancing, or is the market already pricing in future growth?

Most Popular Narrative: 20.5% Undervalued

Travere’s most followed narrative pegs fair value at $53.57, above the last close of $42.59, and builds its case around rare kidney disease revenue potential and margin expansion.

Expansion of FILSPARI's label to include treatment for FSGS, a rare kidney disease with no approved therapies, positions Travere for first-mover advantage in a large, underserved market. If approved, this will create a new, high-margin revenue stream and significantly expand the company's addressable market.

Curious what kind of revenue ramp, margin shift, and earnings multiple are baked into that fair value, and how much growth rests on one core product story.

Result: Fair Value of $53.57 (UNDERVALUED)

However, that story can change quickly if FILSPARI loses ground to new competitors or if regulatory requirements, including REMS and pricing scrutiny, tighten more than expected.

Another Angle On Valuation

The analyst narrative points to Travere trading below fair value, yet the price tag on its current sales tells a more cautious story. The stock sits on a P/S ratio of 7.4x, richer than the fair ratio of 6.3x and above the peer average of 5.7x, which suggests less room for error if growth or margins fall short. So how much valuation risk are you really comfortable taking on here?

Next Steps

With mixed signals on valuation and sentiment, this is the kind of setup where you may want to act quickly, review the data yourself, and weigh both the bullish and cautious angles before deciding what makes sense for you, starting with the 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop here, you risk missing other stocks that could fit your style even better. Give yourself options and scan a few fresh ideas now.

• Spot potential mispricings early by checking out screener containing 21 high quality undiscovered gems that pair solid fundamentals with limited market attention.
• Prioritise resilience by scanning 66 resilient stocks with low risk scores that score well on stability so short term swings do not dominate your portfolio.
• Target balance sheet strength by reviewing the solid balance sheet and fundamentals stocks screener (45 results) and focus on companies that may be better placed to handle shocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.